Sign in Subscribe
Medical centers

Next-Generation Human Liver Organoid Microarray Platform Predicts Drug-Induced Liver Injury

Strategic Insights

— 2 min read

Researchers at Cincinnati Children's Hospital Medical Center, in collaboration with Roche, have developed a next-generation human liver organoid microarray platform that can predict which drugs may cause harmful immune reactions in certain individuals. This innovative platform uses induced pluripotent stem cell-derived liver organoids combined with each donor's autologous CD8 T cells to create a fully human, immune-competent model that mirrors the genetic and immune diversity of real patients. The study, published in the journal Advanced Science, aims to explain why some people experience serious, immune-related liver injuries from otherwise safe medications.

Key Takeaways:

  • The platform can predict which drugs may cause immune-related liver injuries in individuals by recreating hallmark signs of immune-mediated liver toxicity.
  • The study used a patient-specific approach, combining induced pluripotent stem cell-derived liver organoids with each donor's autologous CD8 T cells to create a fully human, immune-competent model.
  • The platform can reproduce complex, patient-specific immune mechanisms that standard lab tests and animal models cannot replicate.
  • The study's co-first author, Fadoua El Abdellaoui Soussi, PhD, and corresponding author, Magdalena Kasendra, PhD, are members of the Center for Stem Cell and Organoid Medicine (CuSTOM) at Cincinnati Children's.
  • The research team recreated liver injury triggered by the antibiotic flucloxacillin, which occurs only in carriers of the HLA-B*57:01 risk gene.
  • The model reproduced hallmark signs of immune-mediated liver toxicity, including T cell activation, cytokine secretion, and hepatocyte damage.
  • The study highlights the importance of combining foundational stem cell science with applied toxicology to develop new tools for predicting drug safety.

Statistics:

  • The study used a patient-specific approach to create a fully human liver system built from stem cells and a patient's own immune cells.
  • The platform can reproduce complex, patient-specific immune mechanisms that standard lab tests and animal models cannot replicate.
  • The study recreated liver injury triggered by the antibiotic flucloxacillin, which occurs only in carriers of the HLA-B*57:01 risk gene.
  • The model reproduced hallmark signs of immune-mediated liver toxicity, including T cell activation, cytokine secretion, and hepatocyte damage.

Sources:

  • "Next-generation human liver organoid microarray platform predicts drug-induced liver injury." Advanced Science, 2025. doi: 10.1002/advs.202500008
  • Cincinnati Children's Hospital Medical Center. "Researchers Develop New Platform to Predict Drug-Induced Liver Injury." Cincinnati Children's Hospital Medical Center, 2025.
  • Roche. "Roche and Cincinnati Children's Hospital Medical Center Collaborate to Develop Next-Generation Human Liver Organoid Microarray Platform." Roche, 2025.

Read more